New Data Forecast More Oral PDE4 Inhibitors for Psoriasis
Medscape 3/24/2023
Orismilast is a new Phosphodiesterase-4 inhibitor, in phase two trials showing promise, is said to be 2 – 5 times more effective than those on the market. The chief competitor will be Daliresp (roflumilast), now generic, that is available for $35/month from Walmart. Another competitor is Otezla (apremilast), available on GoodRx for $4380/month with no generic available. I’m sure the makers of Orismilast will price in the $4,000 – $5000 range or more per month.
Daliresp is approved for COPD treatment, and Otezla is approved for plaque psoriasis.
Anecdotally, Daliresp was noted to help with psoriasis!